Wednesday, March 25, 2026
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Analysis

Institutional Reshuffle at Teradyne: A Deep Dive into Shareholder Movements and Market Momentum

Dieter Jaworski by Dieter Jaworski
December 27, 2025
in Analysis, Semiconductors, TecDAX, Tech & Software, Trading & Momentum
0
Teradyne Stock
0
SHARES
19
VIEWS
Share on FacebookShare on Twitter

A significant realignment is underway among the major shareholders of Teradyne. Recent regulatory filings reveal that institutional investors now control a staggering 99.77% of the company’s outstanding shares, with several prominent funds actively adjusting their stakes. This high concentration sets the stage for pronounced price movements, driven by the capital flows of a few large players. The contrasting actions of Kempner Capital Management, which slashed its position by 46.2%, and new entrant SWS Partners, which acquired 15,866 shares, highlight a divergence in institutional sentiment. The implications for the stock’s trajectory are closely tied to these capital shifts and the underlying demand for the company’s advanced testing equipment.

Financial Performance and Analyst Sentiment

Teradyne’s recent quarterly report provided a solid operational backdrop for these shareholder changes. The company posted revenue of $769.21 million, a year-over-year increase of 4.3%. Earnings per share came in at $0.85, surpassing the consensus estimate of $0.78. The business remains heavily reliant on its semiconductor test division, which contributed $606 million, or approximately 79% of total sales. The Robotics segment generated $75 million (~10%), with Product Test adding $88 million.

Market analysts have responded with a generally positive, though mixed, outlook. The consensus rating sits at “Moderate Buy.” A notable shift came from Goldman Sachs, which upgraded its stance from “Sell” to “Buy,” citing growing demand for test equipment tailored to AI infrastructure. Cantor Fitzgerald maintains an “Overweight” recommendation, emphasizing Teradyne’s strong position in the semiconductor test market. JPMorgan, however, remains more cautious with a “Neutral” rating.

Profitability, Dividends, and Key Metrics

The company’s profitability metrics underscore a robust financial foundation. It reported a return on equity (ROE) of 18.04% and a net margin of 15.49%. A dividend was distributed on December 17, with a payout ratio around 17.45%. From a market perspective, the stock exhibits high volatility, evidenced by a beta of 1.85. It has delivered a strong performance, climbing nearly 50% over the past twelve months. This rally included a streak of six consecutive positive trading days, accompanied by elevated volume that signaled a technical breakout.

Should investors sell immediately? Or is it worth buying Teradyne?

Inside the Institutional Reshuffle and Insider Activity

The disclosed transactions paint a picture of diverging strategies among major funds. The substantial reduction by Kempner Capital Management stands in sharp contrast to the new investment initiated by SWS Partners. Meanwhile, insider ownership remains minimal at just 0.16% of shares. The CEO recently reported a sale of 1,108 shares, reducing his direct holdings by 1.17%.

This environment of extreme institutional ownership makes the equity particularly sensitive to large-scale capital movements. Significant selling from a major fund can create immediate downward pressure, while sustained buying can powerfully reinforce positive technical momentum.

Technical Outlook and Forward Considerations

The stock is currently demonstrating strong technical dynamics, including rising moving averages and the notable volume surge. Its twelve-month outperformance is widely correlated with major investments in cloud and AI infrastructure projects. However, maintaining this momentum is contingent on continued institutional capital inflows and the broader investment cycle for high-precision test systems.

In the near term, increased volatility and corrective pressure are likely if more major funds decide to reduce exposure. Conversely, the upward trend could persist if capital inflows continue and end-market demand holds firm. Key indicators to watch will be future SEC filings detailing fund positions and the upcoming quarterly earnings reports, which will provide further clarity on revenue growth and margin trajectory.

Ad

Teradyne Stock: Buy or Sell?! New Teradyne Analysis from March 25 delivers the answer:

The latest Teradyne figures speak for themselves: Urgent action needed for Teradyne investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from March 25.

Teradyne: Buy or sell? Read more here...

Tags: Teradyne
Dieter Jaworski

Dieter Jaworski

About Dieter Jaworski From a numbers-obsessed child to creating his first investment newsletter. Even as a child, Dieter Jaworski's mother couldn't believe how fascinated he was with numbers. This early passion for mathematics and data analysis laid the foundation for a successful career in financial markets and investment analysis.
Areas of Expertise:
  • Quantitative Analysis
  • Financial Newsletter Publishing
  • Data-Driven Investment Strategies
  • Market Pattern Recognition
Dieter's unique approach combines his natural affinity for numbers with decades of market experience, providing investors with data-driven insights and practical investment strategies.

Related Posts

BioNano Genomics Stock
Analysis

BioNano Genomics Stock: A Tale of Operational Gains and Revenue Headwinds

March 25, 2026
Humacyte Stock
Analysis

Humacyte Shares Hit Record Low Amid Capital Raise and Strategic Shifts

March 25, 2026
Evolent Health Stock
AI & Quantum Computing

Evolent Health Bets on AI Leadership Amid Share Price Decline

March 25, 2026
Next Post
Target Stock

Activist Investor Takes Position in Target, Sparking Turnaround Speculation

Oracle Stock

Oracle's Stock Seeks Footing Amid High-Stakes Cloud Investment

Alphabet Stock

Alphabet Shares Approach Peak Amid Autonomous Driving Setback

Recommended

Alphabet Stock

Alphabet Shares Face Regulatory Headwinds Despite Autonomous Driving Breakthrough

4 months ago
Dish Network Stock

Institutional Investors Show Diverging Views on Dish Network’s Future

7 months ago
Finance_ Trading ratings today (2)

Lakeland Financial Exceeds Expectations with Fourth Quarter Earnings

2 years ago
DeFi Technologies Stock

DeFi Technologies: Navigating Expansion Amidst Legal Headwinds

3 months ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Newsletter
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple ASML BioNTech Bitcoin Bloom Energy Broadcom Coinbase D-Wave Quantum Eli Lilly Fiserv IBM Intel Kraft Heinz Marvell Technology META Micron Microsoft MP Materials MSCI World ETF Newmont Mining NIO Novo Nordisk Nvidia Ocugen Oracle Palantir PayPal Plug Power QuantumScape Realty Income Robinhood Rocket Lab USA Salesforce Strategy Synopsys Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics
No Result
View All Result

Highlights

MongoDB Strengthens Leadership Amid AI-Driven Growth Phase

Talphera Shares Slide as Funding Concerns Overshadow Clinical Progress

Hain Celestial Sheds Snack Division in Strategic Overhaul

Technology Sector Faces Mounting Headwinds as AI Hype Meets Macroeconomic Reality

Lumen’s AI Infrastructure Push Gains Recognition Amid Strategic Overhaul

Microsoft’s AI Ambitions Strain Finances as Cash Reserves Shrink

Trending

BioNano Genomics Stock
Analysis

BioNano Genomics Stock: A Tale of Operational Gains and Revenue Headwinds

by Kennethcix
March 25, 2026
0

BioNano Genomics has wrapped up its fiscal year 2025, presenting a financial picture marked by significant operational...

Humacyte Stock

Humacyte Shares Hit Record Low Amid Capital Raise and Strategic Shifts

March 25, 2026
Evolent Health Stock

Evolent Health Bets on AI Leadership Amid Share Price Decline

March 25, 2026
MongoDB Stock

MongoDB Strengthens Leadership Amid AI-Driven Growth Phase

March 25, 2026
Talphera Stock

Talphera Shares Slide as Funding Concerns Overshadow Clinical Progress

March 25, 2026

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • BioNano Genomics Stock: A Tale of Operational Gains and Revenue Headwinds
  • Humacyte Shares Hit Record Low Amid Capital Raise and Strategic Shifts
  • Evolent Health Bets on AI Leadership Amid Share Price Decline

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com